At a glance
ClinicalIndex Comparison RecordPhase 2Active· 3 enrolled
Drug / intervention
Blinatumomab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Blinatumomab, Mini-CVD, and 1 other intervention for B-cell Acute Lymphoblastic Leukemia. Active but no longer recruiting, targeting 3 participants across 1 site.
Detailed Summary
This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Acute Lymphoblastic Leukemia
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2Active
20262027202820292030203120322033
First PostedSep 2025
Enrollment StartJan 2026
TodayJul 2026
Primary CompletionSep 2031
Study CompletionSep 2033
First PostedSep 4, 2025
Enrollment StartJan 30, 2026
Primary CompletionSep 30, 2031
Study CompletionSep 30, 2033
TodayJul 1, 2026
Enrollment to primary: 5.7 yearsPosted 10 months agoPrimary completion in 5.2 years
Interventions
Blinatumomabdrug
Given by IV
Mini-CVDdrug
Given by IV
MTX/ARA-Cdrug
Given by IV